OMass raises $310 million in Series C financing with Sanofi Ventures participation
OMass Therapeutics announced an oversubscribed $310 million (£230 million) Series C financing on October 15, 2026. The biotechnology company develops small-molecule therapeutics in endocrinology and immunology. Bain Capital Life Sciences, Forbion and Novo Holdings co-led the round; existing investor Sanofi Ventures als